Via The Guardian, Julia Kollewe write: Oxford firm to screen 15,000 drugs in search for coronavirus cureExscientia to use AI to hunt through compounds which have passed human trials
An Oxford-based firm that uses artificial intelligence to develop new medicines has teamed up with a UK national science facility to screen more than 15,000 drugs for their effectiveness as a treatment for Covid-19.
Exscientia, a spinoff company from the University of Dundee that is now based in Oxf...
The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine.
That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other fir...
Architects have designed mobile hospitals in order to provide intensive care to the patients of coronavirus, which can increase their chance of survival.
An Italian design company has teamed up with the Massachusetts Institute of Technology to create prefabricated intensive care units (ICUs), to deal with escalating numbers of coronavirus patients around the world.
Click here for reference
Via MIT NEWS, David L. Chandler write: MIT-based team works on rapid deployment of open-source, low-cost ventilator
Clinical and design considerations will be published online; goal is to support rapid scale-up of device production to alleviate hospital shortages.
One of the most pressing shortages facing hospitals during the Covid-19 emergency is a lack of ventilators. These machines can keep patients breathing when they no longer can on their own, and they can cost around $30,000...
Federal health officials on Friday approved a coronavirus test that can provide results in less than 15 minutes, using the same technology that powers some rapid flu tests.
Teased by Vice President Mike Pence in a Thursday press briefing, the new diagnostic test could accelerate testing in the United States, allowing for rapid results in doctors' offices. But shortages of critical equipment used to collect patient specimens, like masks and swabs, could blunt its impact.
The US Food ...
The coronavirus is not mutating significantly as it circulates through the human population, according to scientists who are closely studying the novel pathogen’s genetic code. That relative stability suggests the virus is less likely to become more or less dangerous as it spreads, and represents encouraging news for researchers hoping to create a long-lasting vaccine.
Scientists now are studying more than 1,000 different samples of the virus, Peter Thielen, a molecular geneticis...
VESper™ is a new device that allows one ventilator to support up to four patients under emergency use authorization by the FDA. Hospitals can apply to receive the free source code and printing specifications for the device.
VESper™ is a unique ventilator expansion device that allows a single ventilator to support up to four patients during times of acute equipment shortages such as the current COVID-19 pandemic.
Produced using 3D printing technology, the device is d...
Spain's Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday.
The plasma will be processed to produce hyperimmune immunoglobins, which will then be put to pre-clinical and clinical tests to see if they can help treat the disease, Grifols said in a statement.
COVID-19 is caused by the corona...
Johnson & Johnson CEO on potential coronavirus vaccine: 'I think we'll have important data by the end of the year'25 Mar, 2020
Via Fox News, Talia Kaplan write: Johnson & Johnson CEO on potential coronavirus vaccine: 'I think we'll have important data by the end of the year'
In an exclusive interview on “Sunday Morning Futures,” Alex Gorsky, the CEO of Johnson & Johnson, discussed his company’s efforts to develop a vaccine for COVID-19, saying, “I think we’ll have important data by the end of the year.”
Gorsky discussed the goals as many hospitals have been overwhelmed am...
Italy recorded a lower day-to-day increase of coronavirus cases for the second day in a row Monday. Italy’s Civil Protection agency documented 4,789 new cases Monday, 700 less than the 5,560 new cases reported Sunday. Also 997 less new cases were reported on Sunday, representing a big drop after their highest levels ever on Friday 20th and Saturday 21st.
Although it is still early to confirm any trend and more data must be collected to say it is a favorable situation, it ...
Via Science, Kai Kupferschmidt and Jon Cohen write: WHO launches global megatrial of the four most promising coronavirus treatments.
A drug combo already used against HIV. A malaria treatment first tested during World War II. A new antiviral whose promise against Ebola fizzled last year.
Could any of these drugs hold the key to saving COVID-19 patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large globa...
Via Science, Robert F. Service write: The standard coronavirus test, if available, works well - but can new diagnostics help in this pandemic?
As the United States races to ramp up testing for the pandemic coronavirus using technology based on the tried-and-true polymerase chain reaction (PCR), alternative approaches are beginning to roll out that could make it easier and quicker for people to learn whether they have been infected. Some methods modify the standard PCR test, wh...